Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.310 +0.030 (+2.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Skye Bioscience, Inc. - Common Stock

News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
From The DJS Law Group
Via Business Wire
News headline image
SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Stockholders Spirit, Molina, Skye, and Perrigo of the Upcoming Deadlines and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused... 
Via Newsfile
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
SKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
MarketBeat Week in Review – 10/7 - 10/11
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. 
Via MarketBeat
News headline image
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure. 
Via MarketBeat
Topics Bankruptcy
News headline image
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
From Beacon Biosignals
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.